-
Site License
-
Site License
-
Enterprisewide
-
Enterprisewide
Challenges and Threats from Bioterrorism: Is the U.S. Prepared?
Frost & Sullivan, October 2001
Long Turnaround Time and Implementation Hurdles Threaten Country‘s Readiness Against Bioterrorism
The threat of bioterrorism has mobilized doctors and public health officials, as
well as pharmaceutical firms and diagnostic test companies, as the U.S.
prepares to defend against possible future attacks. Despite their steadfast
determination, these groups will need to overcome significant practical
challenges as they prepare a nation for possible attacks with biological agents.
The long processing time needed to culture many biological agents, for
example, could impede the ability of healthcare providers to diagnose and
treat patients quickly.
Meanwhile, health officials face technical hurdles implementing a nation-wide
bio-agent response system that demands seamless communication between
medical facilities and public health agencies. This research examines key
systems and industries that will be critical in the war on bioterrorism,
including: healthcare delivery systems, protection and detection equipment,
treatment methods, and communication mechanisms. By identifying potential
obstacles, this study will enable its readers to anticipate challenges and better
contribute to domestic preparedness.
Pharmaceuticals Strive to Balance Preparedness and Profitability
Vaccine developers will see sales and corporate valuations rise as the fear of
a biological warfare attack intensifies, say the study‘s authors. Nevertheless,
due to the low probability of an actual attack, large-scale production of
vaccines may not be cost beneficial to most industry participants.
For others, buying vaccine technologies may be more advantageous than
developing serums in-house. Having concentrated their anti-infective research
and development budgets on more lucrative markets such as central nervous
system and cancer vaccines, large pharmaceutical companies need to license
biowarfare-related products and research from biotechnology firms to fuel
product pipelines, according to the authors. This study offers essential
insights into the pharmaceutical industry‘s endeavors against bioterrorism.
Protective Equipment Sales Expected to Rise
Demand for protective equipment will grow dramatically as states and cities
prepare for chemical and biological attacks, state the analysts. Yet according
to the Department of Defense, procurement contracts for protective
equipment are consolidated within a handful of small, specialized manufacturers.
This supply structure exposes the country‘s preparedness to a great deal of
risk, claim the authors. The government must promote diversification into
non-military markets and encourage new entrants to reduce the vulnerability
of relying on only a few suppliers of protective equipment. This research,
which assesses the impact of bioterrorism preparedness on a range of
markets, will help your company develop effective defense strategies.
Additional Information
Market Participants
3M
Abbott Laboratories, Inc.
Advanced BioSystems/Hadron, Inc.
ANSER Analytic Services, Inc.
Applied Biosystems
ARUP Laboratories
Becton Dickinson and Co.
Bio–Rad Laboratories, Inc.
Camber Corp.
Cepheid
Chemfab, Corp.
Draeger Safety, Inc.
Dupont
Engineered Air Systems, Inc.
Environmental Technologies Group
Essex PB&R
F. Hoffmann La Roche Ltd.
Fisher Scientific International, Inc.
Gen–Probe, Inc.
Geomet Technologies, Inc.
Giat Industries
Guardian Manufacturing Co.
Guild Associates, Inc.
Hunter Manufacturing Co./Hunter Protective
Systems
Hunting Engineering Ltd.
ILC Dover, Inc.
Innogenetics NV
Intellitec
Kappler
Laboratory Corp. of America Holdings
Lakeland Industries, Inc.
Lanx Fabric Systems
Mar Mac/ Chemfab Corp.
Mine Safety Appliances Co.
Molecular Probes, Inc.
Oklahoma City National Memorial Institute for
the Prevention of Terrorism
Ortho–Clinical Diagnostics/Johnson & Johnson Co.
Osborn Scientific Group
QTL Biosystems, LLC
Quest Diagnostics, Inc.
Scott Health & Safety
Tex–Shield, Inc.
Tradeways Ltd.
Trelleborg AB/Trelleborg Protective Products
TVI Corp.
Unilab Corp.
Versar, Inc.
1. Executive Summary
A. Market Overview
1. Executive Summary
2. Introduction
3. Dark Winter Scenarios
4. Major Research Findings
2. Healthcare Delivery System
A. Maximum Preparedness: Best Case Scenarios
1. Healthcare System Overview
2. Maximum Preparedness Overview
3. Maximum Preparedness: Anthrax
4. Maximum Preparedness: Smallpox
B. Lack of Preparedness: Worst Case Scenarios
1. Lack of Preparedness: Anthrax
2. Lack of Preparedness: Smallpox
C. Federal and State Assessment
1. Preparedness
2. Weaknesses
D. Local Assessment
1. Preparedness
2. Weaknesses
3. Protection
A. Overview
1. Introduction
2. Challenges
3. Recommendations
4. Forecasts
5. Manufacturers and Products
B. Personal Protective Equipment
1. Masks/Respiratory Protection Trends
2. Protective Clothing Trends
3. Forecasts
C. Collective Protective Equipment
1. Trends
2. Forecasts
4. Detection
A. Overview
1. Introduction
2. Challenges
3. Recommendations
B. Clinical Detection
1. Technology Analysis & Trends
2. Clinical Laboratory Logistics
C. Environmental Detection
1. Technology Analysis & Trends
2. Competitive Structure
3. Research Methodology
4. Revenue Forecasts
5. Treatment
A. Overview
1. Biological Warfare Treatment Market
Outlook
2. Main Types of Biological Warfare Agents
B. Forecasts and Trends
1. Demand Analysis
2. Revenue Forecasts
3. Market and Technology Trends
C. Competitive Analysis
1. Competitive Structure
2. Product Analysis
6. Communication Mechanisms
A. Market Overview
1. Introduction
2. Forecasts
3. Challenges
4. Research Centers
B. Future Developments
1. Expected Technology Standards
2. Recommendations
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
